Project description
An international data repository network for advanced immunological studies
Many modern therapies involve the adaptive immune system, which has developed a wide range of immune receptors to recognise and remove pathogens and cancer cells. The sequence-data sets characterising this adaptive immune receptor repertoire (AIRR-seq) could revolutionise vaccine research and the development of therapies against autoimmune diseases and cancer. Currently, AIRR-seq data are curated by individual labs, using a variety of tools and technologies. Sharing these data across disease studies and institutions around the world will improve basic and translational research. The EU-funded iReceptor Plus project, comprising a consortium of European and Canadian researchers, addresses the optimisation of sharing AIRR-seq data among public and industrial partners, performing analyses on data from many sources and expanding the size and number of repositories integrated in the network.
Objective
Background: Many cutting-edge therapies rely on manipulating the adaptive immune system, which has evolved a vast diversity (repertoire) of immune receptors to recognize and remove pathogens and cancer cells. The sequence-data sets characterizing this Adaptive Immune Receptor Repertoire (i.e. AIRR-seq data) have the potential to revolutionize vaccine research and the development of therapies against autoimmune diseases and cancer; however, AIRR-seq data are typically stored and curated by individual labs, using a variety of tools and technologies. Sharing these data in a common way across disease studies, labs, and institutions around the world will improve our ability to recognize patterns in basic research and clinical trials, and increase our confidence in these patterns. The existing iReceptor Platform uses community-developed standards to facilitate sharing of AIRR-seq data by enabling queries across a system of distributed data repositories.
Project: The iReceptor Plus consortium of researchers from Europe and Canada will address several key challenges to optimally sharing AIRR-seq data among public and industrial partners: protecting patient privacy and the intellectual property of partners, performing complex analyses on data brought together from many sources, and expanding the size and number of repositories that can be integrated in the network.
Impact: The iReceptor Plus project will facilitate sharing of AIRR-seq data among multiple institutions, including biopharmaceutical companies and researchers working with human confidential data, across multiple diseases, treatments and populations. This will lead to a better understanding of the causes of infectious and autoimmune diseases and cancer, which can lead to early detection and suggest novel therapies. These improvements will reduce the social and economic burden of these diseases, advance Europe and Canada’s leadership role in immunotherapy, and contribute to improved patient care worldwide
Fields of science
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
52900 Ramat Gan
Israel
See on map
Participants (20)
V5A 1S6 Burnaby
See on map
75006 Paris
See on map
M5S 1A1 Toronto
See on map
69120 Heidelberg
See on map
08225 Terrassa
See on map
4200 465 Porto
See on map
31905 Haifa
See on map
0313 Oslo
See on map
4600 109 Amarante
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
27777 Ganderkesee
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
94404 Foster City
See on map
46725 Herziliya
See on map
94566 Pleasanton
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
62098 Tel Aviv
See on map
78701 2982 Austin
See on map
75012 Paris
See on map
Participation ended
0450 Oslo
See on map
1000 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
92103 Jerusalem
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
92545 Jerusalem
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.